MedTrace Logo

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

NCT01047358 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 206

Last updated 2015-10-08

Study results available
· View outcomes & findings →

Summary

This non-interventional study is to monitor use in real practice in Korea including adverse events on Aromasin (Exemestane).

Conditions

Interventions

DRUG

Aromasin

25 mg table QD

DRUG

Aromasin

25 mg table QD

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01047358 on ClinicalTrials.gov